Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Intellia Therapeutics Are Jumping Today

By Jason Hawthorne – Aug 5, 2021 at 3:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

More progress in the pipeline has investors bullish on the company's shares.

What happened

Shares of Intellia Therapeutics (NTLA -7.21%) were up 12% at 3:45 p.m. EDT today after the company reported earnings and updated investors on its clinical trials.

Two researchers staring a a double helix DNA strand.

Image source: Getty Images.

So what

Wall Street was already jazzed over the success of NTLA-2001. That treatment became the first using clustered regularly interspersed short palindromic repeats (CRISPR) gene-editing technology to be successfully deployed directly in humans. Management's update added two more therapies to the list of first-in-human trials it plans this year. Those are its NTLA-2002 for hereditary angioedema, a disease that causes severe swelling, and NTLA-5001 for acute myeloid leukemia.

Now what

After raising funding on the back of the success of NTLA-2001, it makes sense that management would swiftly move other candidates into trials. While the excitement is understandable, investors shouldn't be too surprised. CEO John Leonard shared his intent during the company's first-quarter earnings call with analysts. 

Wall Street may also be encouraged by the updated plans in the NTLA-2001 program. Management believes it will have data by the end of the year in addition to beginning a second part of the trial. Once a single recommended dose is identified, part two of its phase 1 study -- using only that dose -- will begin. It would be impressive to clear all of those milestones inside of a year. It also demonstrates that the company is putting the $600 million it raised in June to work in the right way.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Intellia Therapeutics Stock Quote
Intellia Therapeutics
$38.98 (-7.21%) $-3.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.